CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; Woolston, A; Spain, G; von Loga, K; Challoner, B; Patel, R; Ranes, M; Swain, A; Thomas, J; Bryant, A; Saffery, C; Fotiadis, N; Guettler, S; Mansfield, D; Melcher, A; Powles, T;
Gerlinger, M (reprint author), Inst Canc Res, Ctr Evolut & Canc, Translat Oncogen Lab, 237 Fulham Rd, London SW3 6JB, England.; Gerlinger, M (reprint author), Royal Marsden NHS Fdn Trust, Gastrointestinal Canc Unit, London, England.; Gerlinger, M (reprint
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019; 7 ():